Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product Type (Biologics, Pharmaceuticals, Viscosupplements), By Animal Type (Canine, Feline), By Application, By Route of Administration, By End-use, And Segment Forecasts, 2024

Veterinary Orthopedic Medicine Market Size, Share & Trends Analysis Report By Product Type (Biologics, Pharmaceuticals, Viscosupplements), By Animal Type (Canine, Feline), By Application, By Route of Administration, By End-use, And Segment Forecasts, 2024 - 2030

Veterinary Orthopedic Medicine Market Growth & Trends

The global veterinary orthopedic medicines market size is anticipated to reach USD 6.37 billion by 2030, registering a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing emergence of regenerative medicine and rise in the adoption of viscosupplementation products in veterinary medicine are the major factors contributing to market growth. According to a study conducted by Boehringer Ingelheim and the American Animal Hospital Association (AAHA), in 2022, 1 in 5 dogs i.e., 20% of all dogs experience some joint issue in their lifetime. The majority of animals suffer from Osteoarthritis (OA) because of Developmental Orthopedic Diseases (DODs), with certain breeds more prone to malformed joints than others.

The aim of regenerative medicine in veterinary medicine is to restore normal function to diseased or damaged cells, tissues, etc., including different approaches like cell-based therapies. The use of mesenchymal stromal cells (MSCs), platelet-rich plasma (PRP) & autologous serum products is prominent in this field. Currently, these therapies are used in tendon, ligament, and joint/cartilage treatment in animals like dogs, horses & cats. These treatments are primarily research-based and further concrete clinical reports are under progress. Irrespective of the current use, this branch of veterinary medicine promises effective treatment & management of veterinary diseases.

Current regenerative therapies like MSCs, PRP, etc., fall under the category of drugs. Therefore, FDS regulates them under the category “Cell-based Products”; however, no FDA approval has been given to any of these therapies till now, and the current use falls under FDA investigational exemption. Degenerative Joint Diseases (DJD) and OA cause a rise in friction in the joints. Viscosupplements, such as hyaluronic acid, are intra-articularly injected into the synovial joint of the animal, which further lubricates the joint to reduce friction and assist in smooth movement. Such initiatives are expected to help in the effective management of veterinary orthopedic conditions, thus driving market growth.

Veterinary Orthopedic Medicine Market Report Highlights

• The pharmaceuticals segment accounted for the highest revenue share of more than 51.8% in 2023 owing to the high adoption of products like NSAIDS, steroids, etc. in the treatment of veterinary orthopedic complications
• The canine segment is expected to grow at the fastest CAGR from 2024 to 2030
• The OA segment held the largest market share of 42.0% in 2023. The joint inflammation/pain segment is anticipated to witness the fastest CAGR from 2024 to 2030
• Use of viscosupplements like hyaluronic acid and rising adoption of stem-cell therapy in veterinary complications contributed to market growth
• North America led the market owing to factors, such as increasing prevalence of osteoarthritis, well-equipped veterinary care infrastructure, government support for quality animal care, and high pet adoption in the U.S.
• In August 2022, Bimeda U.S. acquired Afrivet Southern Africa Proprietary Limited, a part of Bimeda’s ongoing expansion program to increase its geographic footprint

Please note The report will be delivered in 2-3 business days upon order notification.